NSPR InspireMD
- 2.280
- -0.020-0.87%
- 2.200
- -0.080-3.51%
InspireMD News
Earnings Call Summary | InspireMD(NSPR.US) Q1 2024 Earnings Conference
The following is a summary of the InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript:Financial Performance:InspireMD reported a Q1 2024 total revenue of $1.5 million, marking an increase of approx
InspireMD Dips on Q1 Figures
InspireMD Cash, Cash Equivalents and Marketable Securities Were $34M at March 31 >NSPR
InspireMD Cash, Cash Equivalents and Marketable Securities Were $34M at March 31 >NSPR
Earnings Flash (NSPR) INSPIREMD Posts Q1 Revenue $1.5M, Vs. Street Est of $1.9M
07:01 AM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (NSPR) INSPIREMD Posts Q1 Revenue $1.5M, vs. Street Est of $1.9M
InspireMD 1Q Loss/Shr 21c >NSPR
InspireMD 1Q Loss/Shr 21c >NSPR
InspireMD (NSPR.US): The 2024 Q1 financial report achieved revenue of US$1,511,000, with a previous value of US$1,239 million, and an expected value of US$1.38 million; earnings per share were -0.21 dollars, previous value was -0.53 dollars, and expected
InspireMD (NSPR.US): The 2024 Q1 financial report achieved revenue of US$1,511,000, with a previous value of US$1,239 million, and an expected value of US$1.38 million; earnings per share were -0.21 dollars, previous value was -0.53 dollars, and expected value was -0.15 dollars.
InspireMD Q1 2024 GAAP EPS $(0.21) Misses $(0.15) Estimate, Sales $1.511B Beat $1.384M Estimate
InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.15) by 40 percent. This is a 60.38 percent increase over losses of $(0.53) per
InspireMD | 10-Q: Quarterly report
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th
TEL AVIV, Israel and MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, today annou
InspireMD Boosts Executive Severance Benefits Ahead of Potential Takeover
InspireMD's (NASDAQ:NSPR) Investors Will Be Pleased With Their Solid 110% Return Over the Last Year
InspireMD to Present Key Trial Results at LINC 2024
InspireMD Announces Abstract Of One-year Follow-up Results From C-GUARDIANS U.S. Investigational Device Exemption Clinical Trial Accepted For Presentation At LINC 2024
InspireMD Announces Abstract Of One-year Follow-up Results From C-GUARDIANS U.S. Investigational Device Exemption Clinical Trial Accepted For Presentation At LINC 2024
Earnings Call Summary | InspireMD(NSPR.US) Q4 2023 Earnings Conference
The following is a summary of the InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript:Financial Performance:InspireMD reported Q4 revenue increase of 71.6% to $1.76 million, significantly driven by
InspireMD GAAP EPS of -$0.16 Beats by $0.03, Revenue of $1.76M Beats by $0.13M
Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M
07:03 AM EST, 03/06/2024 (MT Newswires) -- Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M
InspireMD 4Q Rev $1.76M >NSPR
InspireMD 4Q Rev $1.76M >NSPR
Press Release: InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter
Earnings Scheduled For March 6, 2024
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million. • Foot Locker (NYSE:FL) is likely to report quarterly e
Analysis
Price Target
No Data
